Table 6.
Multivariate analysis for progression free survival (PFS) in Subgroup A and Subgroup B
| |
PFS |
||||
|---|---|---|---|---|---|
| Parameter | SE | HR | 95%CI | WAld’s p | |
|
Subgroup A(1st line, chemo-naïve) | |||||
| Age |
−0.028 |
0.011 |
0.973 |
0.952-0.994 |
0.012 |
| TYMS |
|
|
|
|
|
| aberrant vs. normal |
0.577 |
0.253 |
1.780 |
1.084-2.923 |
0.563 |
| Treatment |
|
|
|
|
|
| platinum vs. taxanes |
0.235 |
0.407 |
1.265 |
0.570-2.811 |
0.563 |
| tax/plat vs. taxanes |
−0.220 |
0.303 |
0.802 |
0.443-1.452 |
0.467 |
| other vs. taxanes |
0.088 |
0.376 |
1.092 |
0.522-2.282 |
0.816 |
| aberrant TYMS *platinum |
−1,687 |
0.564 |
|
|
0.003 |
| aberrant TYMS *tax/plat |
−1.200 |
0.433 |
|
|
0.006 |
|
Subgroup B(1st line, chemo-naïve) | |||||
| Age |
−0.002 |
0.010 |
0.978 |
0.959-0.998 |
0.034 |
| TYMS |
|
|
|
|
|
| aberrant vs. normal |
0.539 |
0.255 |
1.714 |
1.040-2.824 |
0.034 |
| Treatment |
|
|
|
|
|
| platinum vs. taxanes |
0.293 |
0.382 |
1.340 |
0.0633-2.836 |
0.444 |
| tax/plat vs. taxanes |
−0.129 |
0.285 |
0.879 |
0.502-1.537 |
0.650 |
| other vs. taxanes |
−6.631 |
0.439 |
0.532 |
0.225-1.258 |
0.151 |
| aberrant TYMS*platinum |
−1.719 |
0.551 |
|
|
0.002 |
| aberrant TYMS*tax/plat |
−1.233 |
0.420 |
|
|
0.003 |
| aberrant TYMS *other treatment | −1.375 | 0.642 | 0.032 | ||